Mesa Laboratories MLAB Business Segments
| TTM Q4 '26 | TTM Q3 '26 | TTM Q2 '26 | TTM Q1 '26 | TTM Q4 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Business | ||||||
| Biopharmaceutical Development | $48.63M-7.2% | $52.4M+4.2% | $50.26M+4.3% | $48.21M-1.1% | $48.73M+0.9% | |
| Clinical Genomics | $45.39M+1.5% | $44.72M-2.0% | $45.62M-0.8% | $45.97M-2.4% | $47.08M+0.8% | |
| Gross Profit by Business | ||||||
| Biopharmaceutical Development | $28.55M-6.7% | $30.6M+4.7% | $29.22M+3.4% | $28.26M-5.5% | $29.91M-1.2% | |
| Clinical Genomics | $26.03M+4.3% | $24.96M+0.7% | $24.8M+0.8% | $24.61M-4.1% | $25.67M+0.6% | |
| Cost Of Revenue by Business | ||||||
| Biopharmaceutical Development | $20.07M-7.9% | $21.79M+3.6% | $21.04M+5.5% | $19.95M+6.0% | $18.82M+8.9% | |
| Clinical Genomics | $19.36M-2.0% | $19.75M-5.1% | $20.82M-2.6% | $21.37M-0.2% | $21.41M-5.3% | |
| Cost Of Revenue Other by Business | ||||||
| Biopharmaceutical Development | $18.25M-8.8% | $20.01M+3.6% | $19.32M+5.7% | $18.28M+6.2% | $17.22M+9.6% | |
| Clinical Genomics | $18.02M-1.9% | $18.37M-6.0% | $19.55M-2.1% | $19.97M0.0% | $19.97M-1.0% | |
| Inventory Net by Business | ||||||
| Biopharmaceutical Development | $24.06M+7.0% | $22.48M— | —— | —— | —— | |
| Clinical Genomics | $36.18M-3.9% | $37.64M— | —— | —— | —— | |
| Cost Of Goods And Services Sold Depreciation by Business | ||||||
| Biopharmaceutical Development | $308K-3.1% | $318K+8.5% | $293K+9.7% | $267K+19.2% | $224K+9.3% | |
| Clinical Genomics | $578K-6.3% | $617K+22.7% | $503K-20.7% | $634K-6.8% | $680K-9.1% | |
| Goodwill by Business | ||||||
| Biopharmaceutical Development | $200.43M+0.7% | $198.97M— | —— | —— | —— | |
| Clinical Genomics | $68.39M+0.3% | $68.2M— | —— | —— | —— | |
| Cost Of Goods And Services Sold Amortization by Business | ||||||
| Biopharmaceutical Development | $1.51M+2.9% | $1.47M+2.9% | $1.43M+2.1% | $1.4M+2.0% | $1.37M+0.7% | |
| Clinical Genomics | $765K0.0% | $765K0.0% | $765K0.0% | $765K0.0% | $765K-54.6% | |
| Goodwill Foreign Currency Translation Gain Loss by Business | ||||||
| Clinical Genomics | $196K+1.6% | $193K+32.2% | $146K+15.9% | $126K+1,150% | -$12K+85.7% | |
| Revenue by Product | ||||||
| Service | $45.74M+2.8% | $44.5M+1.9% | $43.69M+2.3% | $42.7M+0.3% | $42.58M+1.2% | |
| Revenue by Geography | ||||||
| CN | $20.45M-4.6% | $21.43M-3.1% | $22.11M-8.6% | $24.18M-4.5% | $25.31M-4.9% | |
| Other | $111.79M+3.4% | $108.07M+3.4% | $104.53M+3.7% | $100.77M+1.7% | $99.05M+0.5% | |
| US | $116.9M-1.0% | $118.04M-0.5% | $118.62M+1.0% | $117.4M+0.7% | $116.62M+3.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Mesa Laboratories break its business down?
- Mesa Laboratories (MLAB) reports revenue by business across 3 parts — Biopharmaceutical Development, Calibration Solutions and Clinical Genomics. Each is extracted from the segment footnotes and tracked over time.
- Where does Mesa Laboratories's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Mesa Laboratories's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
